Asthma Trial Design To Be Focus Of Advisory Committee

GSK's investigational LABA could be the most impacted product as FDA's Pulmonary-Allergy Drugs Advisory Committee considers how to evaluate outcomes in the class.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet